GoodRx Holdings, Inc. (GDRX) reported $196.03 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 0.4%. EPS of $0.08 for the same period compares to $0.08 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $193.43 million, representing a surprise of +1.34%. The company delivered an EPS surprise of -11.11%, with the consensus EPS estimate being $0.09.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how GoodRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Monthly Active Consumers: 5 compared to the 5 average estimate based on three analysts.
- Subscription plans: 671 versus 662 estimated by two analysts on average.
- Revenue- Prescription transactions: $127.29 million versus the four-analyst average estimate of $131.26 million. The reported number represents a year-over-year change of -9.3%.
- Revenue- Other: $4.64 million versus $4.5 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -14% change.
- Revenue- Pharma manufacturer solutions: $43.37 million compared to the $37.06 million average estimate based on four analysts. The reported number represents a change of +54.4% year over year.
- Revenue- Subscription: $20.72 million versus $20.26 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2.7% change.
View all Key Company Metrics for GoodRx here>>>
Shares of GoodRx have returned -27.7% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GoodRx Holdings, Inc. (GDRX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
